Clinical Trials
2 trialsNCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03753685 2025-07-23
X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases
Fudan University
Phase 2 Active not recruiting